A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Fluorocyclopentenylcytosine (Primary) ; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 08 Nov 2017 According to a Rexahn Pharmaceuticals media release, first patient has been dosed.
- 26 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 11 Sep 2017 Status changed from not yet recruiting to recruiting according to a Rexahn Pharmaceuticals media release.